Abstract
PharmacokineticsPharmacokineticsand pharmacodynamicsPharmacodynamics operate in a partnership that can be used to maximize a drug’s potential for increasing treatment efficacyEfficacy, reducing side effectsSide effect, and minimizing drug interactionsInteractiondrug; maximizing these parametersParameter will help decide on an optimal dose, ideal administration timingTiming, and an appropriate frequency of the drug. We reviewed individual medicationsMedication used in active tuberculosisTuberculosisactive (TB), the pharmacokineticPharmacokineticsparametersParameter of relevance, and the association of pharmacokineticsPharmacokineticswith pharmacodynamicsPharmacodynamics with treatment efficacyEfficacy. First-line agentsAgentfirst-line, including rifamycins, isoniazid, pyrazinamidePyrazinamide, and ethambutolEthambutol, were evaluated on how to optimize their useAntibiotics. First-line agentsAgentfirst-line highlight the effectivenessEffectiveness of eradicating active TBTuberculosisactive by providing an effective dose from various pharmacokineticPharmacokinetics studies. Second-line antibioticsAntibioticsinclude moxifloxacinMoxifloxacin, amikacinAmikacin, cycloserineCycloserine, bedaquilineBedaquiline, and delamanidDelamanid. The unique pharmacokineticPharmacokinetics properties of each agent were explored. An overview of the standard doses is featured in this review, along with the pharmacokineticPharmacokineticsparameterParameter associated with efficacyEfficacy in addition to therapeutic drug monitoringMonitoring considerations. One of the factors that clinicians can manipulate in managing TB is the pharmacokineticPharmacokineticsparametersParametervia dosingDosingchanges, foodFoodadministration, managementManagement of drug interactionsInteractiondrug, and adherenceAdherence through directly observed therapy.
| Original language | English |
|---|---|
| Title of host publication | Integrated Science |
| Pages | 257-275 |
| Number of pages | 19 |
| DOIs | |
| State | Published - 2023 |
Publication series
| Name | Integrated Science |
|---|---|
| Volume | 11 |
| ISSN (Print) | 2662-9461 |
| ISSN (Electronic) | 2662-947X |
Bibliographical note
Publisher Copyright:© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Pharmacodynamics
- Pharmacokinetics
- Tuberculosis
ASJC Scopus subject areas
- General
Fingerprint
Dive into the research topics of 'The Pharmacokinetic and Pharmacodynamic Properties of Antitubercular Medications'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver